Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AbbVie Inc.ABBV · Entity 2800 | EVP, Finance & Administration | June 26, 2019 | June 28, 2019 |
| GRAIL, Inc.GRAL · Entity 4122 | Director | July 15, 2026 | July 16, 2026 |
| Intellia Therapeutics, Inc.NTLA · Entity 4585 | Director | June 09, 2026 | June 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AbbVie Inc.
Report date June 26, 2019 · Filed June 28, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 169,552 |
Reported balance
After 2019-06-26 transaction · row 1
1 source rowRow 1 · 2019-06-26 · Purchase · Acquired 30,400 · Balance 169,552 |
| Common Stock, $0.01 par valueSEC Table I · non-derivative | IndirectBy spouse | 501 |
Reported balance
Holding disclosure · report date 2019-06-26 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 501 F1: The reporting person disclaims beneficial ownership of all securities held by his spouse. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person disclaims beneficial ownership of all securities held by his spouse.
GRAIL, Inc.
Report date July 15, 2026 · Filed July 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 42,978 |
Reported balance
After 2026-07-15 transaction · row 1
1 source rowRow 1 · 2026-07-15 · Grant · Acquired 276 · Balance 42,978 F1: Represents 276 deferred stock units granted to Mr. Chase under our deferred stock program and 2024 Equity Incentive Plan in lieu of $20,568.49 of cash fees payable to Mr. Chase for his service as a director, based on a price per share of $74.36, which was the closing price per share of the Company's common stock on July 15, 2026. The awards will vest immediately upon grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 276 deferred stock units granted to Mr. Chase under our deferred stock program and 2024 Equity Incentive Plan in lieu of $20,568.49 of cash fees payable to Mr. Chase for his service as a director, based on a price per share of $74.36, which was the closing price per share of the Company's common stock on July 15, 2026. The awards will vest immediately upon grant date.
Intellia Therapeutics, Inc.
Report date June 09, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 143,893 |
Reported balance
After 2026-06-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 9,200 · Balance 143,893 F1: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.89 · Expires 2036-06-08 | Direct | 13,300 |
Reported balance
After 2026-06-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-09 · Grant · Acquired 13,300 · Balance 13,300 F2: This option was granted on June 9, 2026 with respect to 13,300 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
F2: This option was granted on June 9, 2026 with respect to 13,300 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 15, 2026 Filed Jul 16, 2026 20:43 UTC | GRAIL, Inc. GRAL · Entity 4122 | GrantCommon Stock | 276 | $74.36 | $20,523.36 |
DisclosureSEC source: 0001628280-26-048488 · wk-form4_1784234637.xml · nonDerivative · entry 1 CHASE WILLIAM J · CIK 0001563572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,978 F1 · shares: Represents 276 deferred stock units granted to Mr. Chase under our deferred stock program and 2024 Equity Incentive Plan in lieu of $20,568.49 of cash fees payable to Mr. Chase for his service as a director, based on a price per share of $74.36, which was the closing price per share of the Company's common stock on July 15, 2026. The awards will vest immediately upon grant date. Read SEC document |
| June 18, 2026 Filed Jun 22, 2026 21:30 UTC | GRAIL, Inc. GRAL · Entity 4122 | GrantCommon Stock | 5,491 | $63.74 | $349,996.34 |
DisclosureSEC source: 0001628280-26-044736 · wk-form4_1782163820.xml · nonDerivative · entry 1 CHASE WILLIAM J · CIK 0001563572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,702 F1 · shares: Represents an award of 5,491 deferred stock units ("DSUs") granted to Mr. Chase under our 2024 Equity Incentive Plan in lieu of 5,491 restricted stock units. The DSUs will vest in full on the earlier to occur of (i) June 18, 2027 and (ii) the date of the next annual meeting of the Company's stockholders, in each case subject to continued service through the applicable vesting date. Each DSU represents the right to receive, at settlement, one share of common stock. Read SEC document |
| June 09, 2026 Filed Jun 10, 2026 23:00 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 13,300 | $0.00 Strike: $12.89 | $0.00 |
DisclosureSEC source: 0001563572-26-000001 · ownership.xml · derivative · entry 2 CHASE WILLIAM J · CIK 0001563572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,300 Underlying: Common Stock · 13,300 shares Expires 2036-06-08 F2 · derivative.exercise_date: This option was granted on June 9, 2026 with respect to 13,300 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| June 09, 2026 Filed Jun 10, 2026 23:00 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 9,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001563572-26-000001 · ownership.xml · nonDerivative · entry 1 CHASE WILLIAM J · CIK 0001563572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,893 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 20:07 UTC | GRAIL, Inc. GRAL · Entity 4122 | GrantCommon Stock | 408 | $49.79 | $20,314.32 |
DisclosureSEC source: 0001628280-26-025730 · wk-form4_1776456421.xml · nonDerivative · entry 1 CHASE WILLIAM J · CIK 0001563572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,211 F1 · shares: Represents 408 deferred stock units granted to Mr. Chase under our deferred stock program and 2024 Incentive Award Plan in lieu of $20,342.47 of cash fees payable to Mr. Chase for his service as a director, based on a price per share of $49.79, which was the closing price per share of the Company's common stock on April 15, 2026. The awards will vest immediately upon grant date. Read SEC document |
| January 15, 2026 Filed Jan 16, 2026 21:58 UTC | GRAIL, Inc. GRAL · Entity 4122 | GrantCommon Stock | 213 | $97.44 | $20,754.72 |
DisclosureSEC source: 0001628280-26-002435 · wk-form4_1768600702.xml · nonDerivative · entry 1 CHASE WILLIAM J · CIK 0001563572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,803 F1 · shares: Represents 213 deferred stock units granted to Mr. Chase under our deferred stock program and 2024 Incentive Award Plan in lieu of $20,794.52 of cash fees payable to Mr. Chase for his service as a director, based on a price per share of $97.44, which was the closing price per share of the Company's common stock on January 15, 2026. The awards will vest immediately upon grant date. Read SEC document |
| October 15, 2025 Filed Oct 16, 2025 22:17 UTC | GRAIL, Inc. GRAL · Entity 4122 | GrantCommon Stock | 275 | $75.52 | $20,768.00 |
DisclosureSEC source: 0001628280-25-045265 · wk-form4_1760653055.xml · nonDerivative · entry 1 CHASE WILLIAM J · CIK 0001563572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,590 F1 · shares: Represents 275 deferred stock units granted to Mr. Chase under our deferred stock program and 2024 Equity Incentive Plan in lieu of $20,794.52 of cash fees payable to Mr. Chase for his service as a director, based on a price per share of $75.52, which was the closing price per share of the Company's common stock on October 15, 2025. The awards will vest immediately upon grant date. Read SEC document |
| August 20, 2025 Filed Aug 22, 2025 20:30 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | PurchaseCommon Stock | 100,000 | $10.03 | $1,003,000.00 |
DisclosureSEC source: 0000950170-25-110979 · ownership.xml · nonDerivative · entry 1 CHASE WILLIAM J · CIK 0001563572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,693 F1 · kind: Reflects an open market purchase of shares of the Issuer's common stock by the Reporting Person in accordance with the Issuer's trading policies. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.97 to $10.04, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares purchased by the reporting person on August 20, 2025 at each separate price. Read SEC document |
| July 15, 2025 Filed Jul 17, 2025 21:47 UTC | GRAIL, Inc. GRAL · Entity 4122 | GrantCommon Stock | 533 | $38.53 | $20,536.49 |
DisclosureSEC source: 0001699031-25-000158 · wk-form4_1752788856.xml · nonDerivative · entry 1 CHASE WILLIAM J · CIK 0001563572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,315 F1 · shares: Represents 533 deferred stock units granted to Mr. Chase under our deferred stock program and 2024 Equity Incentive Plan in lieu of $20,568.49 of cash fees payable to Mr. Chase for his service as a director, based on a price per share of $38.53, which was the closing price per share of the Company's common stock on July 15, 2025. The awards will vest immediately upon grant date. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:25 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 11,450 | $0.00 Strike: $8.37 | $0.00 |
DisclosureSEC source: 0000950170-25-086231 · ownership.xml · derivative · entry 2 CHASE WILLIAM J · CIK 0001563572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,450 Underlying: Common Stock · 11,450 shares Expires 2035-06-10 F2 · derivative.exercise_date: This option was granted on June 11, 2025 with respect to 11,450 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:25 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-086231 · ownership.xml · nonDerivative · entry 1 CHASE WILLIAM J · CIK 0001563572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,693 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| May 29, 2025 Filed May 30, 2025 23:23 UTC | GRAIL, Inc. GRAL · Entity 4122 | GrantCommon Stock | 6,082 | $41.10 | $249,970.20 |
DisclosureSEC source: 0001699031-25-000129 · wk-form4_1748647406.xml · nonDerivative · entry 1 CHASE WILLIAM J · CIK 0001563572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,782 F1 · shares: Represents an award of 6,082 restricted stock units ("RSUs") granted to Mr. Chase under our 2024 Equity Incentive Plan. The RSUs will vest in full on the earlier to occur of (i) May 29, 2026 and (ii) the date of the next annual meeting of the Company's stockholders, in each case subject to continued service through the applicable vesting date. Each RSU represents the right to receive, at settlement, one share of common stock. Read SEC document |
| April 15, 2025 Filed Apr 16, 2025 22:34 UTC | GRAIL, Inc. GRAL · Entity 4122 | GrantCommon Stock | 784 | $25.94 | $20,336.96 |
DisclosureSEC source: 0001699031-25-000084 · wk-form4_1744842868.xml · nonDerivative · entry 1 CHASE WILLIAM J · CIK 0001563572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,700 F1 · shares: Represents 784 deferred stock units granted to Mr. Chase under our deferred stock program and 2024 Equity Incentive Plan in lieu of $20,342.47 of cash fees payable to Mr. Chase for his service as a director, based on a price per share of $25.94, which was the closing price per share of the Company's common stock on April 15, 2025. The awards will vest immediately upon grant date. Read SEC document |
| January 15, 2025 Filed Jan 16, 2025 21:53 UTC | GRAIL, Inc. GRAL · Entity 4122 | GrantCommon Stock | 1,182 | $17.58 | $20,779.56 |
DisclosureSEC source: 0001628280-25-001746 · wk-form4_1737064416.xml · nonDerivative · entry 1 CHASE WILLIAM J · CIK 0001563572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,916 F1 · shares: Represents 1,182 deferred stock units granted to Mr. Chase under our deferred stock program and 2024 Equity Incentive Plan in lieu of $20,794.52 of cash fees payable to Mr. Chase for his service as a director, based on a price per share of $17.58, which was the closing price per share of the Company's common stock on January 15, 2025. The awards will vest immediately upon grant date. Read SEC document |
| October 30, 2024 Filed Nov 1, 2024 22:17 UTC | GRAIL, Inc. GRAL · Entity 4122 | GrantCommon Stock | 210 | $13.62 | $2,860.20 |
DisclosureSEC source: 0001628280-24-044798 · wk-form4_1730499426.xml · nonDerivative · entry 1 CHASE WILLIAM J · CIK 0001563572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,734 F1 · shares: Represents 210 deferred stock units granted to Mr. Chase under our deferred stock program and 2024 Equity Incentive Plan in lieu of $2,863.01 of cash fees payable to Mr. Chase for his service as a director, based on a price per share of $13.62, which was the closing price per share of the Company's common stock on October 30, 2024. The awards will vest immediately upon grant date. Read SEC document |
| October 15, 2024 Filed Oct 17, 2024 22:33 UTC | GRAIL, Inc. GRAL · Entity 4122 | GrantCommon Stock | 1,054 | $14.01 | $14,766.54 |
DisclosureSEC source: 0001628280-24-043071 · wk-form4_1729204421.xml · nonDerivative · entry 1 CHASE WILLIAM J · CIK 0001563572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,524 F1 · shares: Represents 1,054 deferred stock units granted to Mr. Chase under our deferred stock program and 2024 Equity Incentive Plan in lieu of $14,767.12 of cash fees payable to Mr. Chase for his service as a director, based on a price per share of $14.01, which was the closing price per share of the Company's common stock on October 15, 2024. The awards will vest immediately upon grant date. Read SEC document |
| June 25, 2024 Filed Jun 27, 2024 21:14 UTC | GRAIL, Inc. GRAL · Entity 4122 | GrantCommon Stock | 26,470 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-030363 · wk-form4_1719522849.xml · nonDerivative · entry 1 CHASE WILLIAM J · CIK 0001563572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,470 F1 · shares: Represents an award of 26,470 restricted stock units ("RSUs") which will vest and become payable in three substantially equal annual installments beginning on June 21, 2025, subject to full accelerated vesting upon a change in control of the Issuer. Each RSU represents the right to receive, at settlement, one share of common stock. The RSUs will be settled in common stock upon vesting. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:16 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 11,515 | $0.00 Strike: $25.85 | $0.00 |
DisclosureSEC source: 0000950170-24-073680 · ownership.xml · derivative · entry 2 CHASE WILLIAM J · CIK 0001563572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,515 Underlying: Common Stock · 11,515 shares Expires 2034-06-11 F2 · derivative.exercise_date: This option was granted on June 12, 2024 with respect to 11,515 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:16 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 7,737 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-073680 · ownership.xml · nonDerivative · entry 1 CHASE WILLIAM J · CIK 0001563572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,693 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:30 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 2,447 | $0.00 Strike: $45.20 | $0.00 |
DisclosureSEC source: 0001209191-23-037910 · doc4.xml · derivative · entry 2 CHASE WILLIAM J · CIK 0001563572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,447 Underlying: Common Stock · 2,447 shares Expires 2033-06-13 F2 · derivative.exercise_date: This option was granted on June 14, 2023 with respect to 2,447 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:30 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 1,673 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-037910 · doc4.xml · nonDerivative · entry 1 CHASE WILLIAM J · CIK 0001563572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,956 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| April 14, 2023 Filed Apr 18, 2023 21:04 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (Right to Buy) · Derivative | 14,931 | $0.00 Strike: $38.16 | $0.00 |
DisclosureSEC source: 0000899243-23-011381 · doc4.xml · derivative · entry 2 CHASE WILLIAM J · CIK 0001563572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,931 Underlying: Common Stock · 14,931 shares Expires 2033-04-13 F2 · derivative.exercise_date: This option was granted on April 14, 2023 with respect to 14,931 shares of Common Stock pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan, with 33 1/3 % vesting on April 14, 2024 and the remaining 66 2/3% vesting in 8 substantially equal quarterly installments thereafter. Read SEC document |
| April 14, 2023 Filed Apr 18, 2023 21:04 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 10,483 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-011381 · doc4.xml · nonDerivative · entry 1 CHASE WILLIAM J · CIK 0001563572 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,283 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| June 26, 2019 Filed Jun 28, 2019 20:47 UTC | AbbVie Inc. ABBV · Entity 2800 | PurchaseCommon Stock, $0.01 par value | 30,400 | $67.30 | $2,045,920.00 |
DisclosureSEC source: 0001179110-19-008215 · edgar.xml · nonDerivative · entry 1 CHASE WILLIAM J · CIK 0001563572 · EVP, Finance & Administration 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,552 Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 21:54 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 27,276 | $79.41 | $2,165,987.16 |
DisclosureSEC source: 0001179110-19-003074 · edgar.xml · nonDerivative · entry 1 CHASE WILLIAM J · CIK 0001563572 · EVP, Finance & Administration 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,152 Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:20 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 60,747 | $0.00 Strike: $79.02 | $0.00 |
DisclosureSEC source: 0001179110-19-002371 · edgar.xml · derivative · entry 6 CHASE WILLIAM J · CIK 0001563572 · EVP, Finance & Administration 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,747 Underlying: Common Stock · 60,747 shares Expires 2029-02-20 F6 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 20,249 on February 21, 2020, 20,249 on February 21, 2021, and 20,249 on February 21, 2022. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:20 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 8,481 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002371 · edgar.xml · nonDerivative · entry 4 CHASE WILLIAM J · CIK 0001563572 · EVP, Finance & Administration 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,428 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:20 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 14,989 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002371 · edgar.xml · nonDerivative · entry 3 CHASE WILLIAM J · CIK 0001563572 · EVP, Finance & Administration 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,947 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:20 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 15,945 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002371 · edgar.xml · nonDerivative · entry 2 CHASE WILLIAM J · CIK 0001563572 · EVP, Finance & Administration 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,958 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on adjusted earnings per share and relative total shareholder return measures. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:20 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 22,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002371 · edgar.xml · nonDerivative · entry 1 CHASE WILLIAM J · CIK 0001563572 · EVP, Finance & Administration 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,013 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| December 12, 2018 Filed Dec 14, 2018 22:12 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 60,000 | $90.00 | $5,400,000.00 |
DisclosureSEC source: 0001179110-18-013893 · edgar.xml · nonDerivative · entry 1 CHASE WILLIAM J · CIK 0001563572 · EVP, Finance & Administration 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,863 Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 22:28 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (right to buy) · Derivative | 19,000 | $0.00 Strike: $24.21 | $0.00 |
DisclosureSEC source: 0001179110-18-003333 · edgar.xml · derivative · entry 8 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,000 shares Expires 2021-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 22:28 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (right to buy) · Derivative | 13,400 | $0.00 Strike: $28.31 | $0.00 |
DisclosureSEC source: 0001179110-18-003333 · edgar.xml · derivative · entry 7 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,400 shares Expires 2020-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 22:28 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 32,400 | $114.50 | $3,709,686.60 |
DisclosureSEC source: 0001179110-18-003333 · edgar.xml · nonDerivative · entry 5 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,863 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.27 to $114.67, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 22:28 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon stock, $0.01 par value | 19,000 | $24.21 | $459,955.80 |
DisclosureSEC source: 0001179110-18-003333 · edgar.xml · nonDerivative · entry 4 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,263 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 22:28 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon stock, $0.01 par value | 13,400 | $28.31 | $379,383.48 |
DisclosureSEC source: 0001179110-18-003333 · edgar.xml · nonDerivative · entry 3 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,263 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:28 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 38,528 | $119.44 | $4,601,953.84 |
DisclosureSEC source: 0001179110-18-003333 · edgar.xml · nonDerivative · entry 2 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,863 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.32 to $119.54, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:28 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 28,407 | $118.26 | $3,359,411.82 |
DisclosureSEC source: 0001179110-18-003333 · edgar.xml · nonDerivative · entry 1 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,391 Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:59 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 45,840 | $0.00 Strike: $114.36 | $0.00 |
DisclosureSEC source: 0001179110-18-002305 · edgar.xml · derivative · entry 5 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,840 Underlying: Common Stock · 45,840 shares Expires 2028-02-14 F5 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exercisable in annual increments of 15,280 on February 15, 2019, 15,280 on February 15, 2020, and 15,280 on February 15, 2021. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:59 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 14,991 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002305 · edgar.xml · nonDerivative · entry 3 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,798 F3 · shares: Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:59 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 17,319 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002305 · edgar.xml · nonDerivative · entry 2 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,807 F2 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on adjusted earnings per share and relative total shareholder return measures. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:59 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 15,945 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002305 · edgar.xml · nonDerivative · entry 1 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,488 F1 · shares: Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018. Read SEC document |
| May 18, 2017 Filed May 19, 2017 21:01 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (right to buy) · Derivative | 12,800 | $0.00 Strike: $28.13 | $0.00 |
DisclosureSEC source: 0001179110-17-007635 · edgar.xml · derivative · entry 6 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 12,800 shares Expires 2019-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2017 Filed May 19, 2017 21:01 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (right to buy) · Derivative | 25,500 | $0.00 Strike: $28.86 | $0.00 |
DisclosureSEC source: 0001179110-17-007635 · edgar.xml · derivative · entry 5 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 25,500 shares Expires 2018-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2017 Filed May 19, 2017 21:01 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 38,300 | $65.35 | $2,502,905.00 |
DisclosureSEC source: 0001179110-17-007635 · edgar.xml · nonDerivative · entry 3 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,543 Read SEC document |
| May 18, 2017 Filed May 19, 2017 21:01 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon stock, $0.01 par value | 12,800 | $28.13 | $360,064.00 |
DisclosureSEC source: 0001179110-17-007635 · edgar.xml · nonDerivative · entry 2 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,843 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2017 Filed May 19, 2017 21:01 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon stock, $0.01 par value | 25,500 | $28.86 | $735,930.00 |
DisclosureSEC source: 0001179110-17-007635 · edgar.xml · nonDerivative · entry 1 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,043 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 23:11 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 40,212 | $62.22 | $2,501,990.64 |
DisclosureSEC source: 0001179110-17-003700 · edgar.xml · nonDerivative · entry 1 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,543 Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 22:50 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 100,100 | $0.00 Strike: $61.36 | $0.00 |
DisclosureSEC source: 0001179110-17-002805 · edgar.xml · derivative · entry 4 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,100 Underlying: Common stock · 100,100 shares Expires 2027-02-15 F4 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exercisable in annual increments of 33,367 on 02/16/2018, 33,366 on 02/16/2019, and 33,367 on 02/16/2020. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 22:50 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 15,945 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002805 · edgar.xml · nonDerivative · entry 2 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,755 F2 · shares: Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.